{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["80(4)"],"submitter":["Tellapragada C"],"funding":["Scilife Pandemic Laboratory Preparedness"],"pubmed_abstract":["<h4>Objectives</h4>We aimed to investigate the in vitro activity and genetic determinants of decreased susceptibility (DS; MIC > 4 mg/L) to cefepime/zidebactam of carbapenemase-producing Escherichia coli.<h4>Methods</h4>Clinical isolates (N = 150) of carbapenemase-producing E. coli (CP-EC) belonging to seven distinct STs, isolated at a university clinical microbiology laboratory during 2019-2023 in Stockholm, Sweden were included. MICs for cefepime/zidebactam were determined using the broth microdilution method and interpreted using the tentative EUCAST clinical breakpoints (Susceptible; MIC < 4 mg/L; based on cefepime breakpoint). Whole genome sequences of the isolates were analysed with an emphasis on identifying alterations in PBPs 2 and 3.<h4>Results</h4>Of the 150 isolates, 145 (96.6%"],"journal":["The Journal of antimicrobial chemotherapy"],"pagination":["1137-1140"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11962383"],"repository":["biostudies-literature"],"pubmed_title":["Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2."],"pmcid":["PMC11962383"],"pubmed_authors":["Dunleavy C","Jonsson P","Giske CG","Tellapragada C"],"additional_accession":[]},"is_claimable":false,"name":"Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2.","description":"<h4>Objectives</h4>We aimed to investigate the in vitro activity and genetic determinants of decreased susceptibility (DS; MIC > 4 mg/L) to cefepime/zidebactam of carbapenemase-producing Escherichia coli.<h4>Methods</h4>Clinical isolates (N = 150) of carbapenemase-producing E. coli (CP-EC) belonging to seven distinct STs, isolated at a university clinical microbiology laboratory during 2019-2023 in Stockholm, Sweden were included. MICs for cefepime/zidebactam were determined using the broth microdilution method and interpreted using the tentative EUCAST clinical breakpoints (Susceptible; MIC < 4 mg/L; based on cefepime breakpoint). Whole genome sequences of the isolates were analysed with an emphasis on identifying alterations in PBPs 2 and 3.<h4>Results</h4>Of the 150 isolates, 145 (96.6%","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-11T03:04:08.248Z","creation":"2025-07-11T03:04:08.248Z"},"accession":"S-EPMC11962383","cross_references":{"pubmed":["39960091"],"doi":["10.1093/jac/dkaf045"]}}